Simulating therapeutics using multiscale models of the VEGF receptor system in cancer

Feilim Mac Gabhann, Marianne O. Stefanini, Aleksander S. Popel

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

In recent years, Judah Folkman's vision of anticancer therapeutics based on inhibiting angiogenesis pathways has begun to be realized. In particular, antibodies sequestering VEGF, and small molecule tyrosine kinase inhibitors targeting VEGF receptors, are now approved for various cancers, alone or in combination with other therapies. More are in the development pipeline, with similar or distinct mechanisms of action. The VEGF system is complex, involving multiple ligands and receptors, along with transport throughout the body via the bloodstream. Predicting outcomes of perturbing this system, either by a single agent or combinations, can be aided by in silico models. Here we discuss the ways in which the above drugs target the VEGF pathway in cancer, and describe the development and implementation of multiscale mathematical models to simulate the action of these drugs in order to predict and compare their likely efficacy for various types of tumors.

Original languageEnglish (US)
Title of host publicationModeling Tumor Vasculature
Subtitle of host publicationMolecular, Cellular, and Tissue Level Aspects and Implications
PublisherSpringer New York
Pages37-53
Number of pages17
Volume9781461400523
ISBN (Electronic)9781461400523
ISBN (Print)1461400511, 9781461400516
DOIs
StatePublished - Nov 1 2012

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'Simulating therapeutics using multiscale models of the VEGF receptor system in cancer'. Together they form a unique fingerprint.

Cite this